Janssen Signs a Worldwide Collaboration with Fate Therapeutics for Novel iPSC-Derived Cell-Based Cancer Immunotherapies

Shots:

  • Fate to receive $50M up front and $50M equity investment at $31/ share and funding for the research and development of collaboration candidates through IND filing. The company will receive up to $1.8B as development & regulatory milestones and up to $1.2B as a commercial milestone along with royalties on global sales of products targeting the antigens
  • The collaboration leverages Fate’s iPSC to develop iPSC-derived CAR NK and CAR T-cell therapies while Janssen will provide its antigen-binding domains for up to four tumor-associated antigen targets for hematologic malignancies and solid tumors
  • Fate will advance the candidates up to IND filing, after which Janssen has the right to exercise its option to develop & commercialize the candidates. Additionally, Fate has the right to co-commercialize each candidate with an equal share in profits and losses in the US

Click here ­to­ read full press release/ article | Ref: Fate therapeutics | Image: Twitter